Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Wang, BY; Zhao, WH; Chen, YX; Cao, XM; Yang, Y; Zhang, YL; Wang, FX; Zhang, PY; Lei, B; Gu, LF; Wang, JL; Bai, J; Xu, Y; Wang, XG; Zhang, RL; Wei, LL; Zhuang, QC; Fan, F; Zhang, WG; He, AL; Liu, J

Liu, J (通讯作者)，Xi An Jiao Tong Univ, Dept Hematol, Affiliated Hosp 2, 157 Xiwu Rd, Xian 710004, Peoples R China.

JOURNAL OF MEDICAL CASE REPORTS, 2022; 16 (1):

Abstract

BackgroundMultiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Mu......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索